Temporal patterns, characteristics, and predictors of clinical outcomes in patients undergoing percutaneous coronary intervention for stent thrombosis.


Journal

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040

Informations de publication

Date de publication:
21 Oct 2022
Historique:
pubmed: 24 5 2022
medline: 26 10 2022
entrez: 23 5 2022
Statut: ppublish

Résumé

There are limited data on the outcomes of percutaneous coronary intervention (PCI) following stent thrombosis (ST) and differences exist based on timing. Our aim was to study the rates of PCI procedures for an ST indication among all patients admitted for PCI at a national level and to compare their characteristics and procedural outcomes based on ST timing. All PCI procedures in England and Wales (2014-2020) were retrospectively analysed and stratified by the presence of ST into four groups: non-ST, early ST (0-30 days), late ST (>30-360 days), very late ST (>360 days). Multivariable logistic regression models were performed to assess the odds ratios (OR) of in-hospital MACCE (major adverse cardiovascular and cerebrovascular events, a composite of mortality, acute stroke and reinfarction) and mortality. Overall, 7,923 (1.4%) procedures were for ST indication, most commonly for early ST (n=4,171; 52.6%), followed by very late ST (n=2,801; 35.4%) and late ST (n=951; 12.0%). The rate of PCI for ST declined between 2014 and 2020 (1.7 to 1.4%; p<0.001). Early ST was the only subgroup associated with increased odds of MACCE (OR 1.22, 95% CI: 1.05-1.41), all-cause mortality (OR 1.21, 95% CI: 1.07-1.36) and reinfarction (OR 2.48, 95% CI: 1.48-4.14), compared with non-ST indication. The odds of mortality were significantly reduced in ST patients with the use of intravascular imaging (OR 0.66, 95% CI: 0.48-0.92) and newer P2Y PCI for ST has declined in frequency over a 7-year period, with most procedures performed for early ST. Among the different times of ST onset, only early ST is associated with worse clinical outcomes after PCI. Routine use of intravascular imaging and newer P2Y

Sections du résumé

BACKGROUND BACKGROUND
There are limited data on the outcomes of percutaneous coronary intervention (PCI) following stent thrombosis (ST) and differences exist based on timing.
AIMS OBJECTIVE
Our aim was to study the rates of PCI procedures for an ST indication among all patients admitted for PCI at a national level and to compare their characteristics and procedural outcomes based on ST timing.
METHODS METHODS
All PCI procedures in England and Wales (2014-2020) were retrospectively analysed and stratified by the presence of ST into four groups: non-ST, early ST (0-30 days), late ST (>30-360 days), very late ST (>360 days). Multivariable logistic regression models were performed to assess the odds ratios (OR) of in-hospital MACCE (major adverse cardiovascular and cerebrovascular events, a composite of mortality, acute stroke and reinfarction) and mortality.
RESULTS RESULTS
Overall, 7,923 (1.4%) procedures were for ST indication, most commonly for early ST (n=4,171; 52.6%), followed by very late ST (n=2,801; 35.4%) and late ST (n=951; 12.0%). The rate of PCI for ST declined between 2014 and 2020 (1.7 to 1.4%; p<0.001). Early ST was the only subgroup associated with increased odds of MACCE (OR 1.22, 95% CI: 1.05-1.41), all-cause mortality (OR 1.21, 95% CI: 1.07-1.36) and reinfarction (OR 2.48, 95% CI: 1.48-4.14), compared with non-ST indication. The odds of mortality were significantly reduced in ST patients with the use of intravascular imaging (OR 0.66, 95% CI: 0.48-0.92) and newer P2Y
CONCLUSIONS CONCLUSIONS
PCI for ST has declined in frequency over a 7-year period, with most procedures performed for early ST. Among the different times of ST onset, only early ST is associated with worse clinical outcomes after PCI. Routine use of intravascular imaging and newer P2Y

Identifiants

pubmed: 35599596
pii: EIJ-D-22-00049
doi: 10.4244/EIJ-D-22-00049
pmc: PMC10241267
pii:
doi:

Substances chimiques

Ticagrelor GLH0314RVC
Prasugrel Hydrochloride G89JQ59I13
Platelet Aggregation Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

729-739

Références

J Am Coll Cardiol. 2009 Apr 28;53(17):1488-97
pubmed: 19389558
EuroIntervention. 2020 Dec 04;16(11):e875-e890
pubmed: 32597391
Eur Heart J. 2016 Apr 14;37(15):1208-16
pubmed: 26757787
J Am Coll Cardiol. 2010 Mar 23;55(12):1178-1188
pubmed: 20298923
Angiology. 2018 Oct;69(9):803-811
pubmed: 29656656
J Am Coll Cardiol. 2008 Jun 24;51(25):2396-402
pubmed: 18565395
JACC Cardiovasc Interv. 2014 Oct;7(10):1081-92
pubmed: 25341705
JAMA. 2010 Oct 27;304(16):1821-30
pubmed: 20978260
JACC Cardiovasc Interv. 2013 Dec;6(12):1267-74
pubmed: 24355117
Am J Cardiol. 2020 Mar 1;125(5):720-726
pubmed: 31889525
Circulation. 2016 Apr 26;133(17):1655-67
pubmed: 26969759
Lancet. 2013 Aug 17;382(9892):614-23
pubmed: 23890998
EuroIntervention. 2019 Feb 20;14(14):1435-1534
pubmed: 30667361
EuroIntervention. 2020 Jul 17;16(4):e344-e350
pubmed: 31475906
JAMA. 2005 May 4;293(17):2126-30
pubmed: 15870416
Circulation. 2017 Sep 12;136(11):1007-1021
pubmed: 28720725
Am Heart J. 2009 Aug;158(2):271-6
pubmed: 19619705
J Am Coll Cardiol. 2008 Sep 30;52(14):1134-40
pubmed: 18804739
Eur Heart J. 2015 Dec 14;36(47):3320-31
pubmed: 26417060
Am J Cardiol. 2015 Aug 1;116(3):364-71
pubmed: 26037294
N Engl J Med. 2007 Mar 8;356(10):998-1008
pubmed: 17296824
Circulation. 2011 Sep 13;124(11):1283-7
pubmed: 21911796
Catheter Cardiovasc Interv. 2019 Aug 1;94(2):195-203
pubmed: 30628747
Circulation. 2011 Apr 26;123(16):1745-56
pubmed: 21482968
Heart. 2011 Aug;97(16):1293-7
pubmed: 21719554
Clin Res Cardiol. 2020 Nov;109(11):1381-1391
pubmed: 32239284
J Am Heart Assoc. 2020 Feb 18;9(4):e013606
pubmed: 32063087
J Thromb Thrombolysis. 2021 Apr;51(3):682-692
pubmed: 32691275
Nat Rev Cardiol. 2015 Jun;12(6):325-36
pubmed: 25781415
Circulation. 2007 Mar 20;115(11):1440-55; discussion 1455
pubmed: 17344324
Circulation. 2012 Mar 6;125(9):1110-21
pubmed: 22302840
EuroIntervention. 2013 Dec;9(8):936-44
pubmed: 24384290
Eur Heart J. 2008 Dec;29(24):3011-21
pubmed: 18987096
Circulation. 2018 Jun 12;137(24):2635-2650
pubmed: 29891620
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
Circulation. 2007 Aug 14;116(7):745-54
pubmed: 17664375
J Am Coll Cardiol. 2007 Aug 14;50(7):573-83
pubmed: 17692740

Auteurs

Mohamed O Mohamed (MO)

Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Keele, United Kingdom.
Institute of Health Informatics, University College London, London, United Kingdom.

Alex Sirker (A)

Department of Cardiology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.

Alaide Chieffo (A)

Department of Cardiology, San Raffaele Hospital, Milan, Italy.

Pablo Avanzas (P)

Department of Cardiology, Hospital Universitario Central de Asturias, Oviedo, Spain.

James Nolan (J)

Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom.

Muhammad Rashid (M)

Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Keele, United Kingdom.
Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom.

Mohamed Dafaalla (M)

Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Keele, United Kingdom.
Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom.

Saadiq Moledina (S)

Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Keele, United Kingdom.
Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom.

Peter Ludman (P)

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom.

Tim Kinnaird (T)

Department of Cardiology, University Hospital of Wales, Cardiff, United Kingdom.

Mamas A Mamas (MA)

Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Keele, United Kingdom.
Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH